Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 13/2010

01-09-2010 | Adis Drug Evaluation

Tapentadol Immediate Release

A Review of its Use in the Treatment of Moderate to Severe Acute Pain

Author: James E. Frampton

Published in: Drugs | Issue 13/2010

Login to get access

Abstract

Tapentadol (Nucynta™) is an orally active, centrally acting synthetic analgesic that is thought to exert its analgesic effects via two mechanisms of action (μ-opioid receptor agonism and norepinephrine reuptake inhibition). In the US, the immediate-release (IR) formulation of the drug is approved for the relief of moderate to severe acute pain in patients aged ≥18 years. In the EU, the drug is currently in the marketing authorization process.
In clinical trials in patients with moderate to severe acute (postorthopaedic surgical or musculoskeletal) pain, recommended regimens of tapentadol IR (50–100 mg every 4–6 hours) provided an analgesic effect that was superior to that of placebo, and noninferior or similar to that of oxycodone IR (10 or 15 mg every 4–6 hours). Tapentadol IR therapy was generally well tolerated; it was associated with significant reductions in the incidences of nausea, vomiting and constipation compared with oxycodone IR therapy.
Thus, tapentadol IR is an effective treatment option for the management of moderate to severe acute pain. However, further studies evaluating its clinical utility in relation to that of tramadol and opioids other than oxycodone are warranted. Because tapentadol IR offers the prospect of reduced opioid-related gastrointestinal adverse events while maintaining adequate analgesia, it is a potentially valuable addition to the analgesic armamentarium.
Literature
1.
2.
Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003; 63(1): 17–32PubMedCrossRef
3.
Bates JJ, Foss JF, Murphy DB. Are peripheral opioid antagonists the solution to opioid side effects? Anesth Analg 2004; 98: 116–22PubMedCrossRef
4.
Hatrick CT. Tapentadol immediate release for the relief of moderate-to-severe acute pain. Expert Opin Pharmacother 2009; 10(16): 1–10
5.
Adriaensen H, Vissers K, Noorduin H, et al. Opioid tolerance and dependence: an inevitable consequence of chronic treatment? Acta Anaesthesiol Belg 2003; 54(1): 37–47PubMed
6.
American Academy of Pain Medicine, the American Pain Society and the American Society of Addiction Medicine. Definitions related to the use of opioids for the treatment of pain. WMJ 2001; 100(5): 28–9
7.
Lewis KS, Han NN. Tramadol: a new centrally acting analgesic. Am J Health Syst Pharm 1997 Mar 15; 546: 643–52
8.
Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993 Aug; 46(2): 313–40PubMedCrossRef
9.
Tzschentke TM, Christoph T, Kogel B, et al. (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (Tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharm Exp Ther 2007; 323(1): 265–76CrossRef
10.
Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol hydrochloride: analgesic mu-opioid receptor agonist noradrenaline reuptake inhibitor. Drugs Fut 2006; 31(12): 1053–61CrossRef
11.
12.
Wade W, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther 2009; 31(12): 2804–18PubMedCrossRef
13.
Tzschentke TM, Jahnel U, Kögel B, et al. Tapentadol hydrochloride: a next generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today 2009; 45(7): 483–96PubMed
14.
Daniels S, Casson E, Stegmann JU, et al. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin 2009 Jun; 25(6): 1551–61PubMedCrossRef
15.
Daniels SE, Upmalis D, Okamoto A, et al. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009 Feb 10; 25(3): 765–76PubMedCrossRef
16.
Stegmann JU, Weber H, Steup A, et al. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr Med Res Opin 2008 Oct 10; 24(11): 3185–96PubMedCrossRef
17.
Hartrick C, Van Hove I, Stegmann JU, et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 2009 Feb; 31(2): 260–71PubMedCrossRef
18.
Hale M, Upmalis D, Okamoto A, et al. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin 2009 May; 25(5): 1095–104PubMedCrossRef
19.
Etropolski M, Shapiro D, Okamoto A, et al. Safety and tolerability of tapentadol extended release in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawn phase 3 study [abstract no. 852-P]. Diabetes 2009; 58 Suppl. 1: A226
20.
Lange C, Lange R, Kuperwasser B, et al. Long-term safety of controlled, adjustable doses of tapentadol extended release (ER) and oxycodone controlled release (CR): results of a randomized, open-label, phase 3, 1-year trial in patients with chronic low back or osteoarthritis pain [abstract no. SAT0481]. Ann Rheum Dis 2009; 68 Suppl. 3: 698
21.
Etropolski M, Shapiro D, Okamoto A, et al. Efficacy and safety of tapentadol ER for diabetic peripheral neuropathic pain: results of a randomized-withdrawal, double-blind, placebo-controlled phase III study [abstract no. P05.047]. Neurology 2009 Mar 17; 72 Suppl. 3: A217CrossRef
22.
Buynak R, Shapiro D, Okamoto A, et al. Efficacy, safety, and gastrointestinal tolerability of tapentadol ER in a randomized, double-blind, placebo- and active-controlled phase III study of patients with chronic low back pain [abstract no. 293]. J Pain 2009 Apr; 10 (4 Suppl. 1): S48
23.
Kelly K, Etropolski M, Kuperwasser B, et al. Similar analgesic effect and improved tolerability of tapentadol extended release versus oxycodone controlled release for the treatment of chronic osteoarthritis knee pain: results from a randomized, double-blind, phase 3 trial [abstract no. THU0336]. Ann Rheum Dis 2009; 68 Suppl. 3: 283
24.
Rauschkolb-Loeffler C, Okamoto A, Steup A, et al. Efficacy and tolerability of tapentadol for relief of moderate-to-severe chronic pain due to osteoarthritis of the knee [abstract no. P03.154]. 60th Annual Meeting of the American Academy of Neurology 2009 Apr 12–19; Chicago (IL)
25.
Nucynta™ (tapentadol) immediate-release oral tablets. US prescribing information. Raritan (NJ): Ortho-McNeil-Janssen Pharmaceuticals, Inc., 2008
26.
Christoph T, De Vry J, Tzschentke TM. Anti-allodynic activity of tapentadol in a rat model of neuropathic pain depends on opioid and noradrenergic, but no serotonergic, mechanisms [abstract no. 711]. Eur J Pain 2009; 13 Suppl. 1: S205CrossRef
27.
Schroeder W, De Vry J, Tzschentke TM, et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain. In press
28.
Tzschentke T, De Vry J, Christoph T, et al. Tapentadol HCL: analgesic profile of a novel centrally active analgesic wit a dual mode of action in animal models of nociception, inflammatory, and neuropathic pain [abstract no. 687]. J Pain 2006 Apr; 7 (4 Suppl. 2): S26
29.
Schroeder W, De Vry J, Tzschentke TM. Anti-nociceptive activity of tapentadol in a rat model of acute pain depends on opioid and noradrenergic, but not serotonergic, mechanisms [poster no. 1754]. 6th Triennial Congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) 2009 Sep 9–12; Lisbon
30.
Schroeder W, De Vry J, Tzschentke TM, et al. Differential contribution of opioidergic and noradrenergic mechanisms to the anti-nociceptive and anti-allodynic efficacy of tapentadol in rat models of nociceptive and neuropathic pain [poster]. Neuroscience 2009: The Meeting of the Society for Neuroscience (SfN); 2009 Oct 17–21; Chicago (IL)
31.
Terlinden R, Ossig J, Fliegert F, et al. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet 2007 Jul 30; 32(3): 163–9PubMedCrossRef
32.
Oh C, Etropolski M, Ravenstijn P, et al. Influence of multiple doses of tapentadol IR on QT/QTc interval in healthy subjects [poster]. 2009 Annual Scientific Meeting of the British Pain Society; 2009 Mar 31–Apr 3; Esher, England
33.
Kneip C, Terlinden R, Beier H, et al. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett 2008 Jan; 2(1): 67–75PubMedCrossRef
34.
Mangold B, Oh C, Jaeger D, et al. The pharmacokinetics of tapentadol are not affected by omeprazole: results of a 2-way crossover drug-interaction study in healthy subjects [abstract no. P1 126]. Pain Pract 2007; 7(S1): 55
35.
Smit J, Oh C, Rengelshausen J, et al. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of open-label, crossover drug-drug interaction studies. Pharmacotherapy 2010 Jan; 30(1): 25–34PubMedCrossRef
36.
Smit J, Oh C, Lannie C, et al. Effects of probenecid on tapentadol immediate release pharmacokinetics: results of an open-label, crossover, drug-drug interaction study [abstract no. 61].J Clin Pharmacol 2009; 49: 1104
37.
Smit J, Oh C, Mangold B, et al. Effects of metoclopramide on tapentadol pharmacokinetics: results of an open-label, crossover, drug-drug interaction study [abstract no. 62]. J Clin Pharmacol 2009; 49: 1104
38.
Vorsanger G, Xiang J, Okamoto A, et al. Tapentadol IR versus oxycodone IR for low back or osteoarthritis pain: dose escalation and pain control [abstract no. PB255]. Pain Pract 2009; 9 Suppl. 1: 164–5. Plus poster presented at the 5th World Congress of the World Institute of Pain; 2009 Mar 13–16; New York
39.
Upmalis D, Pei H, Okamoto A, et al. A pooled analysis of the incidence of treatment-emergent adverse events associated with discontinuation in phase 2/3 studies of tapentadol IR [abstract no. 267]. J Pain 2009 May 7; 10 (4 Suppl. 1): S42
40.
Upmalis D, Lange C, Okamoto A, et al. A pooled analysis of the incidence of treatment-emergent adverse events in phase 2/3 studies of tapentadol IR. Pain Pract 2009; 9 Suppl. 1: 163
41.
Upmalis D, Lange C, Okamoto A, et al. Analysis of vital sign changes and electrocardiogram measurements across multiple clinical trials of tapentadol IR [abstract no. PB250]. Pain Pract 2009; 9 Suppl. 1: 163
42.
Upmalis D, Lange C, Okamoto A, et al. A pooled analysis of clinically important renal and hepatic laboratory results in phase 2/3 studies of tapentadol IR [abstract no. PB252]. Pain Pract 2009; 9 Suppl. 1: 163–4
43.
Okamoto A, Upmalis D, Oh C, et al. Safety and tolerability of tapentadol IR for opioid-experienced and non-experienced patient populations after 90 days of exposure in patients with low back pain or osteoarthritis pain [abstract no. PW239]. 12th World Congress on Pain; 2008 Aug 17–22; Glasgow
44.
Vorsanger G, Xiang J, Okamoto A, et al. Tapentadol IR, a new analgesic, vs. oxycodone IR for low back or osteoarthritis pain: influence of prior opioid experience on discontinuation due to nausea and/or vomiting [abstract no. PB254]. Pain Pract 2009; 9 Suppl. 1: 164
45.
Vorsanger G, Xiang J, Okamoto A, et al. Tapentadol IR, a new centrally acting analgesic, versus oxycodone IR for low back or osteoarthritis pain: analyses of treatment discontinuations due to nausea and vomiting [abstract no. PB257]. Pain Pract 2009; 9 Suppl. 1: 165CrossRef
46.
Kavanagh S, Kwong WJ, Hammond G, et al. Constipation symptom severity following tapentadol and oxycodone immediate release (IR) treatment in patients with low back or osteoarthritis pain in a randomized, double-blind, active-controlled study [abstract no. PB244]. Pain Pract 2009; 9 Suppl. 1: 161
47.
Vorsanger G, Xiang J, Okamoto A, et al. Tapentadol IR, a new centrally acting analgesic, versus oxycodone IR for low back or osteoarthritis pain: results of analyses of treatment discontinuations due to constipation [abstract no. PB256]. Pain Pract 2009; 9 Suppl. 1: 165CrossRef
48.
Kavanagh S, Kwong W, Hammond G, et al. Bowel function following tapentadol and oxycodone immediate release treatment in subjects with end stage joint disease: post-hoc analysis of data from a randomized, double-blind, active-and placebo-controlled study [abstract no. 271]. J Pain 2009 Apr; 10 (4 Suppl. 1): S43
49.
Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon. Eur J Pain. Epub 2010 Jul 24
50.
Poulsen L, Arendt-Nielsen L, Brøsen K, et al. The hypoalgesic effect of tramadol in relation to CYP2D6. 1996 Dec; 60(6): 636–44
51.
Klotz U. Tramadol: the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneimittelforschung 2003; 53(10): 681–7PubMed
52.
53.
Tayal G, Grewal A, Mittal R, et al. “Tapentadol”: a novel analgesic. J Anaesth Clin Pharmacol 2009; 25(4): 463–6
54.
Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory. Psychosomatics 2003 Apr; 44: 167–71PubMedCrossRef
55.
Ultram® (tramadol hydrochloride) tablets: US prescribing information. Raritan (NJ): PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., 2009 Sep
56.
Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of tapentadol into schedule II. Final rule. Fed Regist 2009 May 21; 74(97): 23790–3
57.
Oderda GM, Said Q, Evans RS, et al. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother 2007 Mar; 41(3): 400–6PubMedCrossRef
Metadata
Title
Tapentadol Immediate Release
A Review of its Use in the Treatment of Moderate to Severe Acute Pain
Author
James E. Frampton
Publication date
01-09-2010
Publisher
Springer International Publishing
Published in
Drugs / Issue 13/2010
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11204470-000000000-00000

Other articles of this Issue 13/2010

Drugs 13/2010 Go to the issue

Review Article

Pharmacoeconomic Considerations in the Treatment of Multiple Sclerosis

Therapy In Practice

Pyelonephritis in Pregnancy

Leading Article

Novel Antiretroviral Combinations in Treatment-Experienced Patients with HIV Infection

Adis Drug Evaluation

Bendamustine

Review Article

Opioid Formulations Designed to Resist/Deter Abuse

ADis Drug Profile

Guanfacine Extended-Release